Senior leaders in the life sciences are told every week that their organizations are “data rich” and “AI ready.” In practice, many still struggle to answer basic questions about how many eligible patients they truly have, how therapies perform between visits, or why promising models and real‑world evidence (RWE) pilots do not scale. The underlying issue is not a lack of data; it is that the patient data landscape is fragmented, unevenly governed, and often unfit for high‑stakes decisions.[3][2]
This article maps that landscape, explains who actually owns and controls different types of patient data, and outlines why most of it is not AI ready. It then connects the implications directly to the priorities of life science organizational functional unit (clinical development, medical and safety, and commercial and market access) leaders, with concrete questions to guide next steps.[3][2]
Figure 1. Relative maturity of key patient‑data types across structure, longitudinality, clinical richness, representativeness, and AI readiness, adapted from Talon Group Consulting analysis.
From snapshots to movies: How patient data is actually captured
Most life science dashboards still rely on data from a handful of clinic visits and billing events, not continuous signals from patients’ daily lives. These internal clinical, safety, and commercial dashboards are typically built from electronic data capture systems, electronic health records (EHRs), and claims that leaders use to track enrollment, adverse events, prescriptions, and access outcomes. They offer snapshots of how patients look at protocol visits or billing milestones, which can miss the patterns that actually drive risk, response, or discontinuation.[2]
By contrast, newer data streams from wearables, apps, remote monitoring platforms, and patient‑reported outcomes can create something closer to a movie. Instead of a single ECG in the clinic, a wearable can provide a month of heart rhythm and activity patterns that reveal arrhythmias invisible in a 20‑minute appointment window; instead of a single adherence question, connected pill bottles, refill logs, and symptom diaries can show when and why a patient starts missing doses. The intuition behind continuous real‑world data is straightforward, but few organizations have translated it into systematic capabilities at scale, particularly in therapeutic areas where data maturity is lower (Figure 1).[2]
For life science leaders, the tension is simple. Most decisions are still made on the basis of snapshots, while expectations from regulators, payers, and patients increasingly assume that companies can see and act on the full storyline.[3][2]
The main categories of patient data
Although local implementations differ, most patient data used by life science organizations falls into a few broad categories, each with distinct strengths and limitations. Figure 1 summarizes their relative maturity across five attributes that matter for strategy and AI: structure, longitudinality, clinical richness, representativeness, and AI readiness.[2]
Clinical trial data. Clinical trial datasets remain the backbone of regulatory evidence and are often the most structured patient data assets a company controls. Strengths include tight control over inclusion criteria, treatment exposure, and measurement, which supports clean estimation of efficacy and safety under controlled conditions. However, trial populations are often narrowly defined and follow‑up windows can be short relative to the real‑world course of disease, which limits generalizability and can make it difficult to predict how a therapy will perform in more diverse populations and settings.[2]
Electronic health records and clinical notes. EHRs capture diagnoses, procedures, vital signs, lab results, medications, and narrative notes from routine care, and can support disease‑progression models, treatment pathway analyses, and identification of eligible patients for trials. Yet data quality is highly variable, important information is often buried in unstructured text, and documentation incentives can introduce temporal biases that complicate longitudinal analyses.[2]
Claims and billing data. Claims provide longitudinal views of diagnoses, procedures, and pharmacy fills linked to reimbursement, with strengths in coverage, follow‑up length, and standardized coding. The trade‑off is clinical granularity, since claims rarely contain detailed labs, imaging findings, or nuanced clinical assessments, and reflect what was billed rather than what happened clinically in full.[2]
Registries and specialty datasets. Disease registries and specialty datasets, often curated by academic consortia, professional societies, or patient groups, can offer deeper phenotyping, more consistent follow‑up, and intentional capture of outcomes that matter to a particular community. However, they frequently draw from centers of excellence and highly engaged patients, which may not reflect broader practice patterns or populations.[2]
Digital and patient‑generated data. Digital health technologies produce continuous or high‑frequency data on physiology, behavior, symptoms, and engagement, filling gaps between visits when integrated effectively. These data are powerful but noisy, with challenges in device accuracy, patient adherence, and contextualization, and many organizations lack mature pipelines to ingest and interpret them in ways regulators and clinicians can trust.[4][2]
Genomic, imaging, and laboratory data. High‑dimensional modalities such as genomic sequences, advanced imaging, and detailed laboratory panels are essential inputs for precision medicine and many AI models, enabling fine stratification of patient subgroups and prediction of response at a molecular level. Yet these datasets are often siloed within specialized systems and lack standardized linkage to clinical histories, which makes it difficult to connect molecular profiles to longitudinal outcomes at scale.[5][2]
Who owns, buys, and uses patient data
The same patient’s journey can be represented across multiple datasets owned or controlled by different actors, each with distinct incentives. Providers and health systems generate and control most EHR and imaging data, payers and pharmacy benefit managers own claims, and life science sponsors generate trial and certain post‑marketing datasets while licensing access to routine‑care data for research purposes.[2]
Data aggregators and analytics vendors sit in the middle, acquiring and linking EHR, claims, and other sources, then reselling access and tools to sponsors and health systems. Patient advocacy organizations and digital health companies increasingly hold registries and patient‑generated datasets, while regulators and health technology assessment bodies, although not owners of raw data, shape the landscape through their expectations for real‑world evidence and “regulatory‑grade” data. For senior leaders, this means that “our data” is usually a patchwork of internal assets and external licenses governed by law, contracts, and operational norms rather than a clean, unified enterprise architecture.[6][3][2]
Why most of this landscape is not AI ready
Superficially, many organizations have access to vast volumes of patient data, but several structural issues limit how usable these datasets are for AI and advanced analytics. Figure 2 maps five of the most common data issues against the functions that feel their impact most acutely: clinical development, medical and safety, commercial and market access, and digital, data, and AI.[2]
Figure 2. Relative impact of patient‑data challenges (data quality, representativeness, fragmentation, unstructured content, and privacy/contracting) across clinical development, medical and safety, commercial and market access, and digital, data, and AI functions, based on Talon Group Consulting synthesis.
Data quality and completeness remain foundational challenges, with real‑world datasets often containing missing fields, inconsistent units, duplicate records, and highly variable documentation habits. Bias and representativeness are closely related concerns, since many widely used datasets over‑represent certain geographies, academic centers, insured populations, or demographic groups, which can translate directly into inequitable model performance or misleading RWE signals.[7][8][2]
Fragmentation and linkage further complicate matters, because EHR, claims, registries, digital platforms, and genomic systems typically use different identifiers and standards, making reliable longitudinal patient views expensive to build and maintain. Unstructured and multimodal content such as notes, imaging reports, and pathology narratives contain critical signals that are not easily accessible without robust natural language processing and multimodal pipelines that meet regulatory expectations.[4][2]
Finally, privacy, consent, and contractual constraints shape both what is possible and what is permissible. Regulatory regimes like HIPAA and GDPR, along with information‑blocking and interoperability rules under the 21st Century Cures Act and the Trusted Exchange Framework and Common Agreement (TEFCA), define strict boundaries on how data can be linked, de‑identified, and used for secondary purposes. Commercial agreements may further limit use to specific indications, geographies, or products, even when broader reuse would be technically feasible.[1][2]
The net effect is that simply having data does not make an organization AI ready. Turning raw patient data into reliable, defensible inputs for models and RWE programs requires deliberate, ongoing investment in data quality, linkage, governance, and documentation.[7][2]
Why this matters for clinical development leaders
For heads of clinical development and portfolio strategy, the patient data landscape directly affects decisions about which programs to advance, how to design trials, and how to manage operational risk. Weak or fragmented data can lead to optimistic assumptions about addressable populations, underestimation of feasibility challenges, or trial designs that fail to reflect real‑world variability.[2]
Richer and better‑curated data can improve indication selection, support more precise inclusion and exclusion criteria, and inform endpoint strategies that align with both regulatory expectations and payer needs. Linked EHR‑claims‑registry datasets can reveal where patients are actually treated, which comorbidities are prevalent, and how standard of care evolves over time, while continuous data from remote monitoring can reduce uncertainty around adherence, safety, and early response patterns. From a risk perspective, investing in a small number of high‑quality data assets for priority therapeutic areas can pay off more than scattering funds across generic “real‑world data access,” because it directly reduces uncertainty where development decisions have the greatest financial and patient impact.[5][2]
Why this matters for medical and safety leaders
Medical affairs and pharmacovigilance functions depend on high‑quality data to characterize benefit‑risk profiles, detect signals, and respond to emerging evidence. Incomplete, siloed, or biased datasets increase the likelihood of missed safety issues in certain populations, over‑reaction to invalid findings, or misalignment with regulators and clinicians when new information emerges.[3][2]
Access to better linked and better understood data can improve post‑market surveillance, enable more targeted risk management, and support nuanced scientific communication. Integrating spontaneous reports, EHR narratives, and claims‑based outcomes can help differentiate genuine safety signals from artifacts, while patient‑generated data can reveal side‑effect patterns and quality‑of‑life impacts that are invisible in traditional adverse‑event systems. Medical and safety leaders therefore have a critical role in insisting that data readiness and governance are treated as central components of any AI or RWE initiative, including clear definitions of “regulatory‑grade” data for priority indications.[3][2]
Why this matters for commercial and market access leaders
Commercial and market access leaders are increasingly expected to demonstrate real‑world value, not just trial efficacy, to secure coverage, defend pricing, and support value‑based contracts. Payers and health technology assessment bodies are paying close attention to how companies collect, analyze, and present RWE, and they are wary of conclusions drawn from poorly characterized datasets.[6][5][2]
A clear understanding of the patient data landscape helps commercial and access teams decide which questions they can credibly answer, which markets or segments they can support with strong evidence, and where they should push for additional data collection or partnerships. In crowded categories such as obesity, oncology, and cardiometabolic disease, companies that invest in robust, longitudinal, and transparent RWE programs can differentiate themselves with payers, providers, and patient communities, while those relying on generic or opaque data sources risk restricted access and reputational damage.[5][2]
Why this matters for digital, data, and AI leaders
Leaders responsible for digital, data, and AI are under pressure to move from pilots to durable impact, often with ambitious timelines and constrained budgets. Many of the most visible failures in AI deployment stem less from algorithms than from data quality, representativeness, and trust, especially when frontline teams discover that models systematically underperform in their populations.[7][2]
A realistic assessment of the patient data landscape is essential for prioritizing AI investments, because some high‑profile use cases may not be feasible with current data while less glamorous applications could deliver immediate value if aligned to reliable datasets and well‑understood workflows. Digital and AI leaders who can articulate these trade‑offs credibly, and who partner with clinical, medical, and commercial colleagues to improve priority datasets over time, are more likely to build sustainable programs that survive beyond initial pilots.[2]
How senior leaders should respond
No organization can fix every data problem across all therapeutic areas and markets, so the goal is to match ambition to reality and invest where improved data will have the greatest strategic leverage. The figures in this article are a practical starting point: Figure 1 highlights where your current data portfolio is structurally mature or fragile, and Figure 2 clarifies which data issues are most material for each function in your operating model.[2]
First, leaders should decide where they truly need movies rather than snapshots, and for a limited set of priority indications and launches invest accordingly in continuous or high‑frequency data as well as better‑linked EHR and claims assets.
Second, companies should treat patient data assets as part of portfolio strategy, mapping which datasets they own, which they rent, and which they will likely never access at scale so that AI and RWE ambitions stay grounded in reality.[2]
Third, investments should focus on readiness, not just access, including profiling data quality, adopting common standards, building robust linkage pipelines, and establishing cross‑functional governance that turns a small number of datasets into institutional assets.
Finally, incentives across functions need to be aligned so that clinical, medical, safety, commercial, and digital leaders share accountability for how priority datasets are curated and used, and boards regularly ask about the specific data assets and governance structures underpinning AI and digital initiatives.[2]
For executives in the life sciences, the patient data landscape is becoming a central strategic terrain. Those who learn to navigate it deliberately, acknowledging both its potential and its constraints, will be better positioned to turn apparent data richness into real, defensible advantage.[2]
References
“Real‑World Evidence.” Food and Drug Administration, 22 Jan. 2026, www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence.
Framework for FDA’s Real‑World Evidence Program. U.S. Food and Drug Administration, 2018, www.fda.gov/media/120060/download.
Corrigan‑Curay, J., et al. “The New FDA Real‑World Evidence Program to Support Innovation in Drug Development.” Clinical Pharmacology & Therapeutics, vol. 106, no. 1, 2019, pp. 36–39.
Wang, S. V., et al. “The Role of Real‑World Evidence in FDA‑Approved New Drug and Biologics License Applications.” Clinical Pharmacology & Therapeutics, vol. 111, no. 1, 2022, pp. 135–144.
“21st Century Cures Act Requires FDA to Expand the Role of Real‑World Evidence.” Mintz, 19 Dec. 2016, www.mintz.com/insights-center/viewpoints/2146/2016-12-19-1st-century-cures-act-requires-fda-expand-role-real.
“21st Century Cures Act and the Increasing Dependency on Real‑World Data.” Innovaccer, 5 Nov. 2020, innovaccer.com/blogs/21st-century-cures-act-and-the-increasing-dependency-on-real-world-data.
“Information Blocking.” Office of the National Coordinator for Health Information Technology, U.S. Department of Health and Human Services, 25 Mar. 2026, www.healthit.gov/information-blocking/.
“TEFCA, America’s National Interoperability Network, Reaches Nearly 500 Million Health Records Exchanged.” U.S. Department of Health and Human Services, 10 Feb. 2026, www.hhs.gov/press-room/tefca-americas-national-interoperability-network-reaches-nearly-500-million-health-records-exchanged.